Cerebell (CBLL) Q4 2025: TAM Expands 75% as Platform Diversifies Into Delirium and Neonate Markets
Cerebell’s core seizure monitoring business delivered robust growth while the company nearly doubled its total addressable market (TAM) to $3.5 billion through regulatory wins and platform expansion. Strategic bets on delirium and neonatal products are set to drive account penetration and open new revenue streams, but commercial impact from these launches will be back-end loaded into 2026 and beyond. Investors should focus on operational leverage, new account productivity, and the pace of adoption for recently cleared indications as key variables for the company’s next growth phase.
Summary
- TAM Expansion Accelerates Platform Ambitions: Regulatory clearances and new algorithms nearly doubled addressable market size.
- Commercial Execution Drives Account Growth: Expanded sales infrastructure and system-level selling fuel new account additions.
- Growth Levers Shift to New Indications: Neonate, pediatric, and delirium launches position Cerebell for multi-year upside.
Performance Analysis
Cerebell’s Q4 performance reflected a disciplined execution of its recurring revenue model, with strong growth in both product and subscription lines. The company ended the year with 647 active accounts, adding 32 net new accounts in Q4 and 118 for the year, a clear signal that recent investments in commercial infrastructure are gaining traction. The install base remains underpenetrated, with only about 30% of potential utilization tapped, leaving substantial room for further growth within existing accounts.
Gross margins remained high in the upper 80% range, supported by pricing discipline and manufacturing cost controls, although tariffs on China-origin products created modest pressure. Operating expenses increased, reflecting targeted investments in sales, R&D, and public company readiness, but management emphasized that core infrastructure is now largely in place. Cash burn remains manageable, with a $159 million cash position supporting plans to reach cash flow breakeven without additional capital.
- Subscription Upside: Subscription revenue outpaced product growth, reflecting deepening utilization and higher-value offerings like the upcoming neonate product.
- Account Productivity: Newer sales reps are ramping, and system-level selling is expected to drive larger, non-linear account wins.
- Margin Management: Vietnam manufacturing and tariff mitigation efforts are sustaining mid-80% gross margin outlook for 2026.
Overall, the business is positioned for multi-year growth, with much of the commercial impact from new indications and system-level deals likely to materialize in late 2026 and 2027.
Executive Commentary
"We believe we are less than 4% penetrated within a $2.5 billion core seizure market and see significant growth opportunities ahead... With our expanded sales team, FedRAMP approval, and FDA clearance for neonatal and pediatric patients, we have solidified the foundation of our core seizure market to set the stage for exciting 2026."
Jane Chow, Co-founder & Chief Executive Officer
"We plan to selectively deploy capital in incremental R&D and commercial infrastructure investments to capture our untapped market opportunity and maintain rapid long-term revenue growth... We remain committed to our objective to achieve cash flow breakeven with cash on hand."
Scott Blumberg, Chief Financial Officer
Strategic Positioning
1. Platform Expansion Into Adjacencies
Regulatory milestones in 2025 transformed Cerebell from a single-indication seizure company into a multi-indication neural monitoring platform. FDA clearances for neonate and pediatric seizure detection, plus the first-ever delirium detection device, have expanded the company’s TAM from $2 billion to $3.5 billion. The addition of the LVO stroke breakthrough designation further cements the company’s ambition to make EEG a “new vital sign” in acute care.
2. Commercial Infrastructure and System-Level Selling
Expansion from 35 to 55 sales territories and a shift to system-level selling are changing the pace and scale of account wins. Senior territory managers have demonstrated success selling to small and mid-sized hospital systems, and this playbook is now being scaled. The commercial organization is now positioned to drive both new account adds and deeper penetration within existing hospitals, supported by a robust clinical account management (CAM) team.
3. Utilization and Departmental Expansion
Only 30% of the current install base is penetrated, with systematic departmental expansion (e.g., into NICU, ICU, ED) driving higher utilization. Training, protocol development, and cross-indication synergy (seizure, delirium, stroke) are key levers to boost same-store revenue and patient access.
4. Efficient Capital Deployment
Management is leveraging a single platform and sales force to commercialize new indications, minimizing incremental OpEx. R&D spend will remain elevated to support pipeline development, but G&A and sales expenses are expected to moderate as infrastructure scales. Margin discipline and a strong cash position anchor the company’s path to breakeven.
Key Considerations
Cerebell is entering a new phase as it transitions from a single-product, single-market company to a platform play with multiple regulatory-cleared indications and a sharply expanded TAM. The next 18 months will test the company’s ability to convert pipeline and regulatory wins into commercial traction and sustainable margin expansion.
Key Considerations:
- Launch Execution Risk: Commercial impact from neonate and delirium products will be modest in 2026, with meaningful revenue contribution expected in 2027 and beyond.
- Sales Force Productivity: System-level selling and rep maturation are critical for accelerating account wins and utilization within the base.
- Tariff and Supply Chain Management: Ongoing tariff headwinds require continued vigilance in supply chain and manufacturing cost controls.
- Pipeline Leverage: The ability to cross-sell new algorithms and products to the existing install base is a major upside lever if operationalized effectively.
Risks
Key risks include execution on multiple simultaneous product launches, the length and complexity of hospital sales cycles for new indications, and potential margin compression from tariffs or pricing pressure. Litigation expense tied to the Natus patent case is expected to peak in the first half of 2026, and any regulatory or reimbursement delays (e.g., NTAP for delirium) could slow adoption. Management’s guidance embeds conservatism, but upside depends on flawless operational delivery and continued clinical validation.
Forward Outlook
For Q1 2026, Cerebell guided to:
- Continued sequential growth in active accounts and utilization
- Gross margins in the mid-80% range, with tariff mitigation ongoing
For full-year 2026, management guided:
- Total revenue of $111 to $115 million, representing 25% to 29% annual growth
Management highlighted several factors that will shape the year:
- Full commercial launch of neonate and pediatric products in Q2, with financial impact weighted to Q4 and beyond
- Initial pilot for delirium begins in Q2, with commercial impact expected in 2027
Takeaways
Cerebell’s multi-year growth thesis now rests on its ability to operationalize new indications and deepen penetration in both new and existing accounts.
- Execution on Platform Expansion: Regulatory wins have set the stage, but commercial success will require sustained sales force productivity and cross-indication adoption.
- Margin and Cash Discipline: High gross margins and a strong cash position provide a cushion as the company invests in new launches and scales infrastructure.
- 2026 as a Setup Year: Investors should watch for acceleration in system-level deals, same-store utilization, and early signals of neonate and delirium uptake—key drivers for 2027 and beyond.
Conclusion
Cerebell’s Q4 and full-year results confirm the company’s transition to a diversified neural monitoring platform, with regulatory and commercial foundations now in place for multi-year growth. The next phase will be defined by launch execution, sales force leverage, and the ability to turn an expanded TAM into durable revenue and margin gains.
Industry Read-Through
Cerebell’s expansion into delirium and neonate monitoring signals a broader shift in acute care toward integrated, multi-indication brain monitoring platforms. The company’s success with FedRAMP and system-level selling may serve as a blueprint for other medtech firms targeting large, underpenetrated hospital markets. The focus on leveraging existing sales infrastructure for incremental indications is a theme likely to be echoed across digital health and diagnostic device peers, especially as hospitals seek workflow efficiency and multi-use technology investments. Margin management amid tariff volatility remains a sector-wide challenge, and the pace of new indication adoption will be a key differentiator for companies with platform ambitions.